HK1209973A1 - Anthracycline formulations - Google Patents
Anthracycline formulationsInfo
- Publication number
- HK1209973A1 HK1209973A1 HK15111069.6A HK15111069A HK1209973A1 HK 1209973 A1 HK1209973 A1 HK 1209973A1 HK 15111069 A HK15111069 A HK 15111069A HK 1209973 A1 HK1209973 A1 HK 1209973A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- anthracycline
- formulations
- anthracycline formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261737003P | 2012-12-13 | 2012-12-13 | |
PCT/US2013/075002 WO2014093815A1 (en) | 2012-12-13 | 2013-12-13 | Anthracycline formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209973A1 true HK1209973A1 (en) | 2016-04-15 |
Family
ID=50934989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111069.6A HK1209973A1 (en) | 2012-12-13 | 2015-11-10 | Anthracycline formulations |
Country Status (8)
Country | Link |
---|---|
US (2) | US20150342975A1 (xx) |
EP (2) | EP2931042B1 (xx) |
JP (5) | JP6433913B2 (xx) |
AU (1) | AU2013359048A1 (xx) |
CA (1) | CA2894548C (xx) |
DK (1) | DK2931042T3 (xx) |
HK (1) | HK1209973A1 (xx) |
WO (1) | WO2014093815A1 (xx) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6433913B2 (ja) * | 2012-12-13 | 2018-12-05 | サイトレックス コーポレイション | アントラサイクリン製剤 |
NZ631022A (en) | 2013-06-05 | 2018-05-25 | Cytrx Corp | Cytotoxic agents for the treatment of cancer |
KR102211461B1 (ko) | 2015-08-25 | 2021-02-03 | 난토믹스, 엘엘씨 | 고-정확도 변이 판정을 위한 시스템들 및 방법들 |
US11071812B2 (en) * | 2016-05-31 | 2021-07-27 | Penumbra, Inc. | Methods and apparatus for extracting doxorubicin from blood and measuring doxorubicin in blood |
WO2019036485A1 (en) | 2017-08-15 | 2019-02-21 | Nantcell, Inc. | ASSOCIATIONS OF CÉTUXIMAB AND HIGH AFFINITY NATURAL KILLER CELLS AND ASSOCIATED METHODS |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8426672D0 (en) | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
JP2915252B2 (ja) | 1993-06-30 | 1999-07-05 | 明治製菓株式会社 | 溶解性が改善された製剤の製造法 |
AU741439B2 (en) * | 1996-12-30 | 2001-11-29 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
WO2002043765A2 (en) * | 2000-11-28 | 2002-06-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
US20050148534A1 (en) * | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
CA2687291A1 (en) * | 2007-05-16 | 2008-11-20 | Ktb Tumorforschungsgesellschaft Mbh | Low-viscous anthracycline formulation |
EP2216049A1 (en) * | 2009-02-06 | 2010-08-11 | Freie Universität Berlin | Drug conjugates with polyglycerols |
WO2010043049A1 (en) * | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
JP6433913B2 (ja) * | 2012-12-13 | 2018-12-05 | サイトレックス コーポレイション | アントラサイクリン製剤 |
-
2013
- 2013-12-13 JP JP2015547985A patent/JP6433913B2/ja active Active
- 2013-12-13 EP EP13863251.8A patent/EP2931042B1/en active Active
- 2013-12-13 EP EP21169873.3A patent/EP3915369A1/en active Pending
- 2013-12-13 DK DK13863251.8T patent/DK2931042T3/da active
- 2013-12-13 US US14/651,898 patent/US20150342975A1/en not_active Abandoned
- 2013-12-13 CA CA2894548A patent/CA2894548C/en active Active
- 2013-12-13 WO PCT/US2013/075002 patent/WO2014093815A1/en active Application Filing
- 2013-12-13 AU AU2013359048A patent/AU2013359048A1/en not_active Abandoned
-
2015
- 2015-11-10 HK HK15111069.6A patent/HK1209973A1/xx unknown
-
2017
- 2017-05-09 US US15/590,331 patent/US10328093B2/en active Active
-
2018
- 2018-08-01 JP JP2018145172A patent/JP6833768B2/ja active Active
-
2019
- 2019-08-09 JP JP2019147584A patent/JP2019206583A/ja not_active Withdrawn
-
2021
- 2021-05-21 JP JP2021085891A patent/JP7213303B2/ja active Active
- 2021-05-21 JP JP2021085892A patent/JP2021120415A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6433913B2 (ja) | 2018-12-05 |
CA2894548C (en) | 2021-01-12 |
EP3915369A1 (en) | 2021-12-01 |
JP2019206583A (ja) | 2019-12-05 |
WO2014093815A1 (en) | 2014-06-19 |
CA2894548A1 (en) | 2014-06-19 |
US10328093B2 (en) | 2019-06-25 |
JP2021120415A (ja) | 2021-08-19 |
JP2018165280A (ja) | 2018-10-25 |
AU2013359048A1 (en) | 2015-07-02 |
DK2931042T3 (da) | 2021-06-07 |
JP6833768B2 (ja) | 2021-02-24 |
EP2931042A4 (en) | 2016-06-01 |
JP7213303B2 (ja) | 2023-01-26 |
JP2016503026A (ja) | 2016-02-01 |
EP2931042A1 (en) | 2015-10-21 |
EP2931042B1 (en) | 2021-04-28 |
JP2021120414A (ja) | 2021-08-19 |
US20170340655A1 (en) | 2017-11-30 |
US20150342975A1 (en) | 2015-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2300020I1 (hu) | Pirrolobenzodiazepin-antitest konjugátumok | |
HK1255929A1 (zh) | 前體脂質體睾酮製劑 | |
ZA201502523B (en) | Pyrrolobenzodiazepine-anitbody conjugates | |
EP2887958A4 (en) | liposome | |
EP2861218A4 (en) | LIPOSOME FORMULATIONS | |
HK1209973A1 (en) | Anthracycline formulations | |
PL2908835T3 (pl) | Stabilne formulacje | |
RS56980B1 (sr) | Biljne formulacije | |
GB201110278D0 (en) | Formulations | |
GB201221125D0 (en) | Pharmaceutial formulations | |
GB201206178D0 (en) | Formulations | |
GB201111578D0 (en) | Pharmeutical formulations | |
GB201111013D0 (en) | Formulations | |
GB201107626D0 (en) | Formulations | |
GB201107627D0 (en) | Formulations | |
GB201105410D0 (en) | Formulations | |
GB201105360D0 (en) | Formulations | |
GB201104048D0 (en) | Formulations | |
GB201104049D0 (en) | Formulations | |
GB201102795D0 (en) | Formulations |